Tag: Cagent Vascular
Cagent Vascular initiates patient enrolment in Serranator vs. plain balloon angioplasty...
Cagent Vascular has announced its first patient enrolment of the Serranator versus plain balloon angioplasty optical coherence tomography (OCT) study.
This prospective, randomised (2:1 treatment...
Cagent Vascular launches Serranator SL-PRO for CLTI and pedal disease
Cagent Vascular has announced the launch of the Serranator SL-PRO percutaneous transluminal angioplasty (PTA) serration balloon catheter for chronic limb-threatening ischaemia (CLTI) and pedal...
Cagent Vascular initiates the Serranator POINT FORCE observational registry
Cagent Vascular has announced the start of the POINT FORCE registry, a postmarket clinical follow-up study of the Serranator percutaneous transluminal angioplasty (PTA) serration...
Cagent Vascular raises US$30 million series C financing
Cagent Vascular has announced a series C financing close in excess of US$30 million. US Venture Partners (USVP) led the round. Participation included new...
RECOIL study: Serranator demonstrates 49% less recoil than plain balloon angioplasty...
Cagent Vascular has announced the results of its below-the-knee (BTK) RECOIL study. This core lab-adjudicated Recoil analysis— the first of its kind, according to...
PRELUDE-BTK subanalysis “suggests advantage” for serration angioplasty
Cagent Vascular has announced the results of a comparative subanalysis of the PRELUDE-below-the-knee (BTK) study versus plain balloon angioplasty.
The study was led by Marianne...
Sectoral Asset Management makes US$9 million investment into Cagent Vascular
Cagent Vascular recently announced the investment of US$9 million by Sectoral Asset Management. Along with the investment, Marc-Andre Marcotte has joined the board of...
LINC 2021: PRELUDE-BTK results confirm Serranator device novel mechanism of action
Cagent Vascular announced the results of its PRELUDE-BTK study at LINC 2021 (25–29 January, online). The PRELUDE-BTK study was a prospective, single-arm, multicentre feasibility...
Cagent Vascular raises US$11.87M funding
Cagent Vascular has announced the completion of US$11.87 million in Series B funding. The round was led by two strategic investors including one that...
